207 related articles for article (PubMed ID: 36044718)
1. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
[TBL] [Abstract][Full Text] [Related]
2. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
3. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
4. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N
Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876
[TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.
Wildey G; Shay AM; McColl KS; Yoon S; Shatat MA; Perwez A; Spainhower KB; Kresak AM; Lipka M; Yang M; Behtaj M; Fu P; Alahmadi A; Mneimneh W; Abbas A; Dowlati A
Mol Cancer Ther; 2023 Feb; 22(2):264-273. PubMed ID: 36399634
[TBL] [Abstract][Full Text] [Related]
6. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Rudin CM; Balli D; Lai WV; Richards AL; Nguyen E; Egger JV; Choudhury NJ; Sen T; Chow A; Poirier JT; Geese WJ; Hellmann MD; Forslund A
J Thorac Oncol; 2023 Sep; 18(9):1222-1232. PubMed ID: 37210008
[TBL] [Abstract][Full Text] [Related]
8. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
[TBL] [Abstract][Full Text] [Related]
9. Clinical correlation of extensive-stage small-cell lung cancer genomics.
Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
[TBL] [Abstract][Full Text] [Related]
10. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
[No Abstract] [Full Text] [Related]
12. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko TK; Park K; Govindan R; Ready N; Reck M; Peters S; Dakhil SR; Navarro A; Rodríguez-Cid J; Schenker M; Lee JS; Gutierrez V; Percent I; Morgensztern D; Barrios CH; Greillier L; Baka S; Patel M; Lin WH; Selvaggi G; Baudelet C; Baden J; Pandya D; Doshi P; Kim HR
J Clin Oncol; 2021 Apr; 39(12):1349-1359. PubMed ID: 33683919
[TBL] [Abstract][Full Text] [Related]
13.
Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
[TBL] [Abstract][Full Text] [Related]
14. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
17. Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?
Sonkin D; Thomas A; Teicher BA
Lung Cancer Manag; 2019 Aug; 8(2):LMT13. PubMed ID: 31645891
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
